Therapeutic inhibition of galectin‑3 improves cardiomyocyte apoptosis and survival during heart failure

治疗性抑制半乳糖凝集素 3 可改善心力衰竭期间心肌细胞凋亡和存活率

阅读:8
作者:Xia Li, Xuan Tang, Jinping Lu, Sheng Yuan

Abstract

Galectin-3 is an important mediator of cardiac fibrosis and heart failure. Cell viability of cardiomyocytes was measured using a CCK‑8 assay; flow cytometry was employed for the detection of the cell cycle and cardiomyocytes apoptosis. Reverse transcription‑quantitative polymerase chain reaction and western blotting was performed to examine the expression of associated genes and proteins. The present study demonstrated that overexpression of galectin‑3 significantly decreased the viability of cardiomyocytes in a time‑dependent manner, with simultaneous arrest of the cell cycle and induction of apoptosis. The expression levels of proliferating cell nuclear antigen (PCNA) and B‑cell lymphoma 2 (Bcl‑2) were decreased and Bcl‑2‑associated X protein (Bax) was increased in cardiomyocytes with galectin‑3 overexpression. However, inhibition of galectin‑3 by intravenous tail vein injection of a galectin‑3‑targeting short hairpin RNA‑expressing vector during hypertension‑induced heart failure in Dahl hypertensive rats increased rat survival and body weight. Inhibition of galectin‑3 also increased the expression of PCNA and Bcl‑2 and reduced the expression of Bax in the cardiac tissue of hypertensive rats. These results demonstrate the therapeutic potential of targetinggalectin‑3 for the treatment of cardiac disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。